They are not for human consumption or therapeutic application
GLP-1RA Reward Behaviour Systematic Review (PubMed, 2024) GLP-1 Receptor Signalling in Reward Circuitry, Dopamine, and Addiction Research A systematic review of GLP-1 receptor agonist effects on reward behaviour published on PubMed following PRISMA guidelines across OVID, PubMed, Scopus, and Google Scholar evaluated the evidence for GLP-1Rs role in reward dysfunction across obesity, type 2 diabetes, and psychiatric conditions
Khadija Ahmed, orcid.org/0000-0002-9310-062X
Expert Opin Drug Discovery (2014) 9:122351
Current data from clinical trials indicate that retatrutide, administered via subcutaneous injection, demonstrates a predictable and manageable safety profile, consistent with other incretin-based therapeutics